healthcare – Market Industry Forecast News

U.S. Nuclear Medicine Market Boosted by Cancer and Neurology Applications

The U.S. nuclear medicine market size was estimated at USD 5.1 billion in 2023 and is projected to grow at a CAGR of 12.6% from 2024 to 2030. This growth is primarily driven by the increasing prevalence of cancer and cardiovascular diseases across the country. According to the American Cancer Society, the U.S. recorded approximately 1,958,310 new cancer cases in 2023, with 609,820 projected cancer-related deaths. The demand for nuclear medicine is further fueled by technological advancements and the growing need for precise diagnostic and treatment solutions.

Cardiovascular diseases remain the leading cause of death among most racial and ethnic groups in the U.S. As per a CDC report published in May 2023, around 805,000 Americans experience heart attacks annually, with 605,000 undergoing their first episode. To combat this, the U.S. government allocated nearly USD 239 billion annually between 2018 and 2019 for heart disease prevention and treatment, encompassing medication and healthcare services. Lifestyle factors such as alcohol consumption, unhealthy diets, and physical inactivity contribute significantly to the prevalence of cancer and heart diseases, thereby escalating the demand for nuclear medicine solutions.

The market is further driven by continuous technological innovation. Radiopharmaceuticals have transformed diagnostic and therapeutic practices in cardiology and oncology. Ongoing research highlights the efficacy of radioisotopes in treating a variety of health conditions, including cancer, thyroid disorders, respiratory ailments, bone issues, and gastrointestinal diseases. This scientific momentum is leading to the development of advanced nuclear medicine products for diagnostic and therapeutic use. For example, Siemens Healthineers introduced the Symbia Pro.specta in June 2022—an advanced SPECT and CT imaging system—which received both U.S. FDA clearance and CE mark approval for broad clinical application. Its features include automated workflows, SPECT motion correction for improved imaging, and a low-dose CT of up to 64 slices, setting it apart in the competitive landscape.

The demand for accurate diagnostic tools continues to rise, with Positron Emission Tomography (PET) gaining traction due to its precision in targeted organ analysis. PET scans offer superior accuracy compared to traditional diagnostic methods and are instrumental in evaluating treatment efficacy. Frequently combined with X-rays or CT scans, PET enhances diagnostic detail. In October 2023, Positrigo AG launched its NeuroLF PET system in the U.S. via its local subsidiary, reinforcing the importance of R&D and innovation in nuclear imaging technologies.

Order a free sample PDF of the U.S. Nuclear Medicine Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

By Product: Diagnostic products held a dominant share, accounting for 71.2% of total revenue in 2023.
By End-use: Hospitals and clinics were the leading end-users in 2023.
By Application: The oncology segment led the market by application share in 2023.

Market Size & Forecast

2023 Market Size: USD 5.1 billion
2030 Projected Market Size: USD 12.27 billion
CAGR (2024–2030): 12.6%

Key U.S. Nuclear Medicine Company Insights

Prominent market players such as GE Healthcare, Cardinal Health, Lantheus Medical Imaging, Siemens Healthineers AG, and Novartis leverage established regional networks to maintain stringent quality standards and secure competitive market shares. These companies invest significantly in advanced technologies and infrastructure to support high-volume diagnostics and therapies. Strategic partnerships and distributor collaborations further strengthen their positions.

Emerging players like NTP Radioisotopes SOC Ltd., Eczacıbaşı-Monrol, Lantheus Medical Imaging, and Nordion (Canada), Inc. are gaining visibility by securing government and institutional funding and launching novel products to address unmet needs in the U.S. market.

Key U.S. Nuclear Medicine Companies:

Eckert & Ziegler
Curium
GE Healthcare
Jubilant Life Sciences Ltd.
Bracco Imaging S.P.A
Nordion (Canada), Inc.
The Institute for Radioelements (IRE)
NTP Radioisotopes SOC Ltd.
Eczacıbaşı-Monrol
Lantheus Medical Imaging, Inc.
The Australian Nuclear Science and Technology Organization
Novartis (Advanced Accelerator Applications)
Siemens Healthineers AG

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The U.S. nuclear medicine market is poised for substantial growth due to a convergence of factors, including the rising burden of cancer and cardiovascular diseases, rapid technological innovations, and increasing investment in advanced imaging and therapeutic solutions. The adoption of highly accurate diagnostic tools such as PET and SPECT systems, combined with robust R&D activities and supportive government initiatives, will continue to drive the market forward. As major and emerging players expand their capabilities and partnerships, the landscape is set to evolve with new innovations catering to the growing demand for personalized and efficient healthcare solutions.

Bioanalytical Testing Services Market Fueled by Increasing Focus on Biomarker Testing

The global bioanalytical testing services market was valued at USD 4.73 billion in 2024 and is anticipated to expand at a CAGR of 9.21% from 2025 to 2030. This growth is driven by the rising volume of drug development activities, increasing drug approval processes, growing therapeutic complexity, and a surge in outsourcing of testing services. The emergence of complex therapeutic modalities—such as gene therapies and biologics—has heightened the demand for specialized bioanalytical testing services. Additionally, technological advancements and rising investments in research and development are key contributors to market expansion.

The continuous evolution of advanced technologies—including High-Throughput Screening (HTS), Liquid Chromatography-Mass Spectrometry (LC-MS), and Next-Generation Sequencing (NGS)—has significantly enhanced the accuracy, speed, and sensitivity of bioanalytical testing. These innovations empower service providers to conduct more sophisticated studies and obtain precise data regarding drug efficacy, safety, pharmacokinetics, and more. Furthermore, the integration of automation and Artificial Intelligence (AI) within bioanalytical workflows has streamlined operations, minimized human error, and boosted throughput.

Moreover, heightened regulatory oversight and growing awareness of the critical role of bioanalytical testing are also fueling demand for these services. The implementation of stricter guidelines governing drug development—especially in pharmacokinetics, pharmacodynamics, and bioequivalence testing—by regulatory agencies like the U.S. FDA and EMA has led to a stronger inclination toward outsourcing. These regulations emphasize the necessity for accurate, reliable bioanalytical methods to ensure the safety and effectiveness of new drugs and biosimilars.

Pricing Analysis

The bioanalytical testing services sector utilizes various pricing models tailored to specific project requirements and levels of client engagement. Milestone-based pricing is widely adopted for projects with clearly defined stages, such as method development and sample analysis, enabling payments to be linked with the achievement of deliverables. This approach provides predictability for sponsors while aligning payments with progress for service providers. Fixed-fee pricing is more suitable for routine testing services—including bioequivalence and pharmacokinetic studies—where standardization leads to minimal variability.

Get a preview of the latest developments in the Bioanalytical Testing Services Market! Download your FREE sample PDF today and explore key data and trends

Molecule Insights

The small molecule segment held the largest market share at 55.3% in 2024. This dominance is attributed to breakthroughs in small molecule therapeutics and persistent unmet medical needs. Bioanalytical testing of small molecules plays a pivotal role in understanding their ADME (Absorption, Distribution, Metabolism, and Excretion) profiles, determining appropriate dosing, evaluating therapeutic efficacy, and ensuring patient safety.

Test Insights

In 2024, the bioavailability segment led the market. Its growth stems from its vital role in drug development and regulatory approval processes. Bioavailability studies are essential for assessing how effectively and rapidly a drug reaches systemic circulation, directly impacting dosage formulation, therapeutic efficacy, and safety. This segment is crucial for evaluating both new chemical entities and generic formulations to ensure consistent performance and compliance with bioequivalence standards.

Workflow Insights

The sample analysis segment was the dominant workflow category in 2024. This segment encompasses processes such as quantification of active pharmaceutical ingredients, metabolite detection, and stability testing—each critical for regulatory submissions and clinical trial advancement. As drug pipelines become more complex, especially with the rise of biologics and targeted therapies, demand for accurate, high-throughput sample analysis is expected to increase.

End Use Insights

In 2024, the pharma & biopharma companies segment accounted for the largest market share. This growth reflects the increasing reliance on outsourcing specialized testing throughout the drug development lifecycle. Pharmaceutical and biopharmaceutical companies are increasingly turning to external service providers to navigate the complex, highly regulated bioanalytical workflows—including pharmacokinetic assessments, immunogenicity testing, and biomarker validation. Outsourcing enables these companies to accelerate development timelines, reduce internal infrastructure costs, and access specialized expertise and advanced technologies.

Regional Insights

North America represented the largest share of the global bioanalytical testing services market, accounting for 47.40% in 2024. Growth in this region is propelled by rising demand for biopharmaceuticals, continuous technological innovation, and increased R&D investment in novel drug development. Advancements in mass spectrometry, chromatography, and other analytical techniques have further improved the sensitivity, specificity, and throughput of bioanalytical testing. These innovations enable laboratories to conduct more precise and efficient analyses, supporting faster drug development timelines and lowering costs.

Leading Companies in the Bioanalytical Testing Services Market

The following companies are key players in the bioanalytical testing services market, collectively holding a significant share and shaping industry trends:

Thermo Fisher Scientific Inc.
ICON Plc
Charles River Laboratories International
IQVIA Inc.
Syneos Health
SGS SA
Labcorp
Intertek Group Plc
Pace Analytical Services LLC
WuXi AppTec

Gather more insights about the market drivers, restrains and growth of the Bioanalytical Testing Services Market

Pathology Laboratories Market Gains Momentum with Increasing Cancer Screening

The global pathology laboratories market was valued at USD 386.18 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2030. This growth is primarily fueled by the expansion of healthcare facilities in developing regions, rising demand for routine medical examinations, and improvements in reimbursement policies for diagnostic tests. Additional drivers include an aging global population and the increasing prevalence of chronic diseases. Moreover, the market is benefiting from the establishment of new laboratories in emerging markets. For example, in August 2024, Neuberg Diagnostics launched a new laboratory facility in Puducherry, India, offering radiology, wellness, and pathology services.

As chronic diseases become more widespread, the demand for robust healthcare systems and timely diagnostics continues to rise. Early and accurate diagnosis is essential for effective management of chronic conditions, leading to greater reliance on clinical diagnostics. According to the World Health Organization, the global senior population is expected to increase from 1 billion in 2020 to 1.5 billion by 2030, with one in six people worldwide aged 60 or older. Chronic illnesses are especially common among older adults; the National Council on Aging reports that 80% of U.S. adults aged 65 and above have at least one chronic condition, emphasizing the critical need for regular health screenings in this age group.

The trend toward routine health check-ups is also on the rise. Given the high incidence of chronic conditions, individuals over 40 are strongly encouraged to undergo regular health screenings. Meanwhile, the growing occurrence of chronic diseases among younger adults has led to increased demand for preventive check-ups within this demographic. Heightened health awareness has motivated more individuals to prioritize routine medical evaluations.

In addition, many countries require employers to provide annual health assessments for their employees, creating further demand for diagnostic laboratory services. Increased healthcare spending aimed at improving infrastructure in developing nations has also contributed to the establishment of new hospitals and diagnostic labs, along with upgrades to existing facilities. For instance, in March 2022, the Delhi government announced plans to upgrade 15 hospitals and build four new hospitals in the city, boosting the expansion of hospital-based diagnostic centers.

Type Insights
In 2024, the hospital-based segment led the market, accounting for 55.7% of total revenue. The growth of hospital-based laboratories is driven by several factors: the rising burden of chronic diseases necessitating prompt and accurate diagnostics; technological advancements that enhance testing efficiency and accuracy; and the growing emphasis on patient-centered care, encouraging integration of laboratory services with clinical operations to improve outcomes. Furthermore, favorable reimbursement policies and the increasing demand for routine health screenings continue to support the expansion of hospital-based labs within healthcare systems.

Testing Services Insights
The general physiological and clinical tests segment held the largest market share in 2024, representing 39.2% of the total. These tests—including blood counts, metabolic panels, and urinalysis—are fundamental tools for diagnosing diverse health conditions and monitoring patient health. Their broad use across primary care, outpatient clinics, and hospitals sustains steady demand, as they are vital for early disease detection and effective treatment planning.

Get a preview of the latest developments in the Global Pathology Laboratories Market! Download your FREE sample PDF today and explore key data and trends

End-use Insights
In 2024, physician referrals accounted for 51.7% of the overall market share. Approximately 70% of physicians’ medical decisions depend on diagnostic and pathological test results, underscoring the critical role of laboratory testing in clinical decision-making. The increasing prevalence of targeted diseases across various age groups is expected to further drive the growth of this segment.

Regional Insights
North America dominated the global pathology laboratories market in 2024, capturing a 37.87% revenue share. The region’s leadership is attributed to its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and well-established regulatory environment. Additionally, rising rates of chronic diseases, growing demand for personalized medicine, and increasing healthcare expenditures contribute to North America’s prominent position in the global market.

Key Pathology Laboratories Companies
The leading companies shaping the pathology laboratories market include:

Quest Diagnostics Incorporated
Eurofins Scientific
Laboratory Corporation of America Holdings
Exact Sciences Laboratories LLC
Spectra Laboratories
SYNLAB International GmbH
Sonic Healthcare Limited
Dr. Lal Path Labs
Metropolis Healthcare
Kingmed Diagnostics
Healius Limited
BioReference
Centro de Diagnósticos
Falco Holdings
Unilabs

Gather more insights about the market drivers, restrains and growth of the Pathology Laboratories Market

Gene Therapy Market Propelled by Innovation in Viral and Non-Viral Vectors

The global gene therapy market was valued at USD 5.54 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. This growth is driven by several key factors, including the rising advancement in therapeutic technologies and gene delivery methods, as well as intensifying competition among major industry players aiming to commercialize their therapies. Biotechnology firms are actively pursuing mergers, acquisitions, collaborations, and strategic partnerships to build internal expertise and strengthen their product pipelines.

The COVID-19 pandemic had an adverse impact on market performance. The industry faced significant disruptions in supply chains, production capabilities, and logistics operations. For example, certain companies experienced prolonged delays in obtaining specific components and later encountered shortages in clinical trial supplies after one of their contract manufacturing partners was forced to cease operations.

Despite this, the market is expected to gain momentum in the coming years, supported by a strong development pipeline. Researchers are striving to bring gene therapy into routine clinical practice. Numerous academic institutions and research centers have an extensive range of products under development, which is projected to contribute to revenue growth throughout the forecast period. Notably, clinical trials for gene therapy surged following the FDA’s approval of the first gene therapy in 2017. According to the American Society of Gene & Cell Therapy (ASGCT), there are currently approximately 1,986 gene therapy-related products in development, including CAR T-cell therapies and other genetically engineered cell treatments.

In addition, evolving regulatory frameworks are expected to foster further growth. Several global regulatory agencies have implemented positive changes to facilitate the advancement of gene therapies. For instance, the FDA has expressed strong support for CAR-T cell technology. During Phase II and III clinical studies, regulators are showing increased flexibility in the traditional trial structure. The FDA anticipates approving between 10 and 20 new gene therapies annually by 2025.

Increased funding and investment in gene therapy is also projected to offer promising growth prospects for industry players. Many biopharmaceutical companies are channeling resources into the development of new products. For example, Ori Biotech secured over USD 100.0 million in Series B funding in January 2022 to launch an innovative platform for cell and gene therapy development, enabling a swift progression from pre-commercialization to full market entry.

Get a preview of the latest developments in the Global Gene Therapy Market! Download your FREE sample PDF today and explore key data and trends

Regional Overview
In 2023, North America led the global gene therapy market, capturing a revenue share of 18.95%. This dominance is expected to continue throughout the forecast period, both in terms of regulatory approvals and revenue generation. Strong investment in research and development by both established and emerging companies is anticipated to drive further market expansion in the region.

Leading Companies in the Gene Therapy Market:
The key players shaping the gene therapy landscape and holding significant market shares include:

Amgen Inc.
Novartis AG
F. Hoffmann-La Roche
Gilead Sciences, Inc.
bluebird bio, Inc.
Bristol-Myers Squibb Company
Legend Biotech
BioMarin
uniQure N.V.
Merck & Co.
Sarepta Therapeutics, Inc.
Krystal Biotech, Inc.
CRISPR Therapeutics

Gather more insights about the market drivers, restrains and growth of the Gene Therapy Market

U.S. Dialysis Centers Market Sees Expansion with Growing Investments in Dialysis Infrastructure

The U.S. dialysis centers market size is expected to reach USD 40.39 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.4% from 2025 to 2030. The high prevalence of End-Stage Renal Disease (ESRD) and favorable reimbursement are some of the key factors expected to boost growth. The expenditure on treatment is gradually rising due to the increasing prevalence of ESRD.

The availability of Medicare reimbursement for kidney disorder treatment is increasing the accessibility to the treatment. The Center for Medicare & Medicaid Services announced a new end-stage renal diseases treatment choice model for the maintenance & improvement in the reimbursement for chronic kidney disorder patients. The new model is encouraging the use of home-based treatment. In August 2022, the CMS expanded the eligibility for reimbursement for kidney disorder treatment. The expansion includes certain capital assets, mainly equipment used at home for treatment. This is increasing the accessibility to the services.

The patients need to travel to and fro the center for around 3 days per week, the proximity from the patient’s residence is generally an important criterion for the center of choice. Hence the launch of new facilities is a key strategic initiative undertaken by major players to increase their market share. For instance, in May 2021, U.S. Renal Care, Inc. inaugurated three new facilities, one in-center facility and two focusing on home therapies. This expanded the company’s presence in the Southwest Florida region.

The COVID-19 pandemic resulted in patients facing difficulty in having an access to treatment for end-stage renal disorder, requiring multiple sessions within a month. According to the national kidney foundation, 15.8% of the patients undergoing treatment for end-stage renal disease had COVID-19 infection. The federal government & service providers promoted home treatment. In June 2021, a new campaign innovative kidney care was launched by nine leading healthcare organizations for patient options for receiving home treatment.

Get a preview of the latest developments in the U.S. Dialysis Centers Market! Download your FREE sample PDF today and explore key data and trends

U.S. Dialysis Centers Market Report Highlights

Based on service, the in-center segment held the largest revenue share in 2024. This can be attributed to the need for assistance & care for the procedure, which can be facilitated better at the centers. The high preference for hemodialysis is also driving the market opportunity as it essentially requires center visits & assistance.
Based on dialysis type, hemodialysis dominated the market in 2024. This can be attributed to the preference for the segment by healthcare professionals & longer life expectancy for patients. However peritoneal dialysis is expected to have the fastest growth during the forecast period owing to the effective removal of toxic substances & high convenience of peritoneal dialysis enabling patients to independently have treatment at home.
Based on facility type, dialysis chains dominated the market in 2024. This can be attributed to the presence of such chains throughout the U.S. The availability of top-quality equipment and treatment at a lower cost compared to hospital-based facilities is driving the segment’s growth. In addition, the key players are acquiring independent facilities, resulting in most of the independent facilities being managed by chains.
The service providers and patients faced challenges since the onset of the COVID-19 pandemic, some of which are unique as compared to other health facilities and treatment groups. For instance, hemodialysis (HD) patients visit centers at least three times a week and during each session, the patients are exposed to all the patients concurrently receiving treatment in a particular session, and to healthcare personnel along with any additional exposure during their travel to and from the center.
Mergers & acquisitions and collaborations are being preferred by the key players, enabling them to have a competitive edge by adding value to their services. For Instance, in March 2022, Fresenius Medical Care announced a merger with InterWell Health and Cricket Health for facilitating better kidney disorder solutions.

List of Key Players in the U.S. Dialysis Centers Market

Fresenius Medical Care AG
S. Renal Care, Inc.
DaVita Inc.
Innovative Renal Care
DCI
SATELLITE HEALTHCARE
Northwest Kidney Centers
Centers for Dialysis Care
Rogosin Institute
Dialysis Care Center
USCF Health (The Regents of The University of California)
Rhode Island Hospital, Department of Health Rhode Island
University of Iowa Hospital & Clinics
Saint Anthony Hospital
Rush University Children’s Hospital

Gather more insights about the market drivers, restrains and growth of the U.S. Dialysis Centers Market

Hospital Bed Management Systems Market Promotes Collaboration Across Departments

The global hospital bed management systems market size is expected to reach USD 3.8 billion by 2030, according to a new report by Grand View Research, Inc, expanding at a CAGR of 10.31% from 2023 to 2030. The key factors driving the market growth include the rising incidence of chronic and infectious diseases, increasing geriatric population, and growing adoption of real-time bed management in hospitals. Furthermore, increasing awareness of hospital supportive and friendly software for smooth functioning of bed allotment and rising number of hospitals and clinics are contributing to the market growth. As a result, the demand for growing need for hospital bed management systems is expected to rise in the near future.

Hospitals lose quality suffering and millions due to cancellations, diversions and delays around bed management. The key challenges faced by hospitals include poor coordination among caregivers, lack of data on bed status resulting in hidden beds, inefficient discharge procedures, and deprived forecasting on bed demand from hospital wards, intensive care units, and other specialized areas. Hospital bed management systems are designed to help healthcare organizations manage and maintain their hospital beds.

Order a free sample PDF of the Hospital Bed Management Systems Market Intelligence Study, published by Grand View Research.

The software offers a variety of features including optimized bed management, allocation, and tracking for effective hospital management. These features focus on improved patient care, boost overall efficiency, and enhance resource utilization. In addition, hospital bed management systems offer automated workflows, real-time communications, escalation notifications, and reduced patient wait times by coordination.

Furthermore, major players in the market are undertaking several strategic initiatives owing to the rising adoption of automation technologies. For instance, in March 2023, Masimo and Temple Health entered into collaboration with focus on hospital automation and telehealth initiatives to improve life, improve patient outcomes, and reduce the cost of care. Similarly, LeanTaaS completed the acquisition of intelligent automation solutions provider Hospital IQ developing an AI-powered hospital operations software provider valued at about USD 1 billion.

Moreover, growing government funding and initiatives are anticipated to boost market growth. As per the HIMSS Future of Healthcare Report, 80% of healthcare providers plan to boost investments in technology and digital solutions within the next five years. This initiative is projected to drive growth in various sectors, including hospital automation technologies including hospital bed management systems.

Hospital Bed Management Systems Market Report Highlights

Based on the type, the market is segmented into acute care beds, critical care bed and long-term care bed, and others.
The acute care bed segment is anticipated to dominate the global market in 2022 and expected to grow at a fastest CAGR of 10.68% during the forecast period. The growth is attributed to increasing acute care admission of patients for one to three days at the healthcare facilities.
On the basis of deployment mode, the web & cloud-based segment dominated the market with a maximum revenue share in 2022. The growth is attributed to the need to reduce maintenance expenses and ensure the smooth operation of medical equipment.
North America dominated the market with a revenue share of 40.9% in 2022. The growth of the region is driven by factors such as the increase in the increasing investments in healthcare infrastructure, rise in disposable income, and the thriving medical tourism industry in the region.
The Asia Pacific region is predicted to experience significant growth during the forecast period, owing to large patient pool, increased end-user awareness, and heavy government investment in digital transformation in the region.

List of Key Players of Hospital Bed Management Systems Market

Oracle
Epic Systems Corporation
GE Healthcare
Veradigm LLC
CentralSquare Technologies
Advanced Data Systems
Terawe Corp
Lyngsoe Systems A/S
The Access Group
EMIS Health
TeleTracking Technologies, Inc.
SAP

Gather more insights about the market drivers, restrains and growth of the Global Hospital Bed Management Systems Market

Patient Engagement Solutions Market Challenges: Addressing User Adoption and Trust Issues

The global patient engagement solutions market was valued at approximately USD 22.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.7% from 2024 to 2030. Key drivers for this growth include ongoing technological advancements, the increasing adoption of Electronic Health Records (EHR) and mobile health (mHealth) solutions, the rising prevalence of chronic diseases, supportive initiatives from major stakeholders, and a growing consumer focus on healthcare. A survey conducted by NextGen Healthcare in 2021 revealed that 83% of ambulatory healthcare providers believe that patient engagement solutions are essential for achieving both financial success and improved patient outcomes, with the COVID-19 pandemic further accelerating market growth.

Gather more insights about the market drivers, restrains and growth of the Global Patient Engagement Solutions Market

Segmentation Analysis:

Delivery Type Insights

In 2023, the web and cloud-based segment dominated the market, holding a substantial 78.0% revenue share, and is projected to experience the fastest growth throughout the forecast period. The increasing adoption of these solutions is attributed to their ability to provide remote access to real-time data tracking, integrated features, easy accessibility, low handling costs, and straightforward data backup. Consequently, companies are increasingly investing in web and cloud-based patient engagement solutions. For instance, Microsoft introduced Microsoft Cloud for Healthcare in May 2020, aiming to enhance patient engagement and facilitate collaboration among healthcare teams through telehealth and data analytics capabilities.

On-premise services also play a crucial role, offering secure patient data management and ease of access, driven by the desire for comprehensive information access within healthcare facilities.

Component Insights

The software and hardware segment accounted for the largest revenue share of 62.7% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. These components form the core offerings of patient engagement solutions, providing intuitive user interfaces and continuous product upgrades that simplify installation, usage, and record retrieval. An example is FollowMyHealth from Allscripts, a widely used mobile-first, customizable patient engagement solution that enhances care quality and patient satisfaction.

The services segment is essential for the effective operation of patient engagement solutions, aiding in their optimization based on customer needs and maximizing health outcomes. This segment encompasses consulting, implementation, training, support and maintenance, as well as services related to interoperability and access to EHR data.

Functionality Insights

In 2023, the communication segment held the largest revenue share at 35.0%, forming the foundational offering of any patient engagement solution. This dominance is driven by the growing demand for telehealth, mHealth, and various virtual communication channels, including audio, video, and text. The pandemic accelerated the adoption of these virtual communication solutions, extending their applications to remote patient monitoring and mental health services.

The health tracking and insights segment is projected to grow at the fastest rate of 19.1% over the forecast period, fueled by the increasing integration of data analytics, artificial intelligence (AI), and machine learning to provide actionable insights for patients and their healthcare providers. For instance, Nuance Communications, Inc. introduced Nuance Mix, a conversational AI platform utilizing deep learning-based speech and natural language understanding technologies. In September 2021, Leidos partnered with Nuance to incorporate this platform and its omnichannel development tools into custom patient engagement solutions.

End-use Insights

The providers segment captured the largest revenue share, exceeding 47.0% in 2023. Providers, who cater to the highest volume of patients and serve as the primary point of contact for health consultations, are the leading adopters of patient engagement solutions. For example, in December 2021, Northwell Health in the U.S. implemented a patient engagement platform by Playback Health at select clinical sites, promoting mobility and secure sharing of point-of-care medical data.

Conversely, the payers segment is expected to grow at the fastest rate of 18.0% during the forecast period. The expansion of this segment is attributed to the increasing adoption of patient and customer engagement solutions that enable broad coverage and support value-based care delivery. Payers are focusing on managing patient care and ensuring connectivity at every stage of the treatment process.

Therapeutic Area Insights

Chronic disease management dominated the market in 2023, holding a revenue share of over 44.7%. The growing geriatric population in key markets, along with the rising prevalence of chronic diseases and accelerated adoption of digital technologies driven by the COVID-19 pandemic, have significantly contributed to the segment’s large share. Patient engagement solutions facilitate chronic disease management by enabling prevention and detection of conditions and supporting both provider-led and self-management strategies.

The health and wellness segment is projected to experience the fastest growth rate of 18.0% over the forecast period, driven by initiatives from leading companies, an expansion of product offerings covering mental health, weight management, and pregnancy, as well as increased research activities. For instance, in June 2023, Cardinal Health finalized an agreement to transfer its Outcomes business to Transaction Data Systems, enhancing patient engagement and clinical pharmacy solutions, thereby strengthening connections between payers and pharmaceutical companies within its extensive pharmacy network.

Application Insights

Outpatient health management accounted for over 39.0% of the market share in 2023, highlighting its dominance. The segment encompassing research and development (R&D) and preventive care is expected to grow at the fastest rate of 18.0% throughout the forecast period. Patients with chronic conditions require continuous monitoring and updates regarding their health management. The rise of healthcare consumerism has also led patients to become more engaged in care planning, tracking, and optimization.

Patient engagement solutions enable remote connections between patients and their healthcare providers, facilitating the efficient exchange of information, patient feedback, and other health-related data. For example, in November 2019, the CDC funded 13 state-level arthritis management and prevention programs to enhance the quality of life and monitoring for rural arthritis patients. Additionally, the adoption of patient engagement solutions for R&D purposes by medical device manufacturers, pharmaceutical companies, and other life sciences entities is expected to grow significantly due to increasing product availability and demand.

Order a free sample PDF of the Patient Engagement Solutions Market Intelligence Study, published by Grand View Research.

Non-small Cell Lung Cancer Therapeutics Market Predictions: What Lies Ahead in 2025

The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Access the Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment (Chemotherapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Non-small Cell Lung Cancer Therapeutics Market Report Highlights

The adenocarcinoma segment dominated the market in 2023 with a share of 43.3% in 2023 due to increase in the population consuming tobacco and other products for smoking.

The targeted therapy segment dominated the market in 2023 with a share of 50.5% in 2023. The factors responsible for the market growth are the benefits of this therapy such as increased number of targeted therapeutics and low percentage of side effects during the treatment.

The hospital pharmacy segment dominated the market in 2023 with a share of 66.7% in 2023. This market growth was attributed to the increase in the number of hospitalized patients suffering from NSCLC.

North America dominated the non-small cell lung cancer therapeutics market with a market share of 35.4% in 2023. This growth was attributed to the presence of developed healthcare facilities and increased awareness regarding cancer treatments.

Key Non-small Cell Lung Cancer Therapeutics Company Insights

Some of the major companies in the non-small cell lung cancer therapeutics market are F.Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. Companies are focusing on deploying new drugs and therapies in order to deal with the rising demand for lung cancer patients.

Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with health care providers, governments and local communities to support and expand access to health care around the world.

F.Hoffmann-La Roche Ltd. Is a multinational healthcare company that operates in the pharmaceutical and diagnostics divisions. The company is a major provider of cancer treatments globally.

Order your free sample copy of “Non-small Cell Lung Cancer Therapeutics Market Report 2024 – 2030, published by Grand View Research

Key Non-small Cell Lung Cancer Therapeutics Companies:

The following are the leading companies in the non-small cell lung cancer therapeutics market. These companies collectively hold the largest market share and dictate industry trends.

F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
GSK plc
Novartis AG
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.

Recent Developments

In May 2024, Pfizer Inc. announced longer-term follow-up results from the phase 3 CROWN trial evaluating LORBRENA versus XALKORI for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After 5 years of median follow-up, there was an 81% reduction in the disease progression rate.

In March 2023, F.Hoffmann-La Roche Ltd. announced the approval of VENTANA PD-L1 (SP263) Assay as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients. The company believed that with this launch, more patients will have access to an additional immunotherapy option.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com

Bipolar Disorder Market Performance: Evaluating Drug Efficacy and Safety

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient’s mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation’s Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Access the Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient’s mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights

The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.

The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.

The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.

North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.

Order your free sample copy of “Bipolar Disorder Market Report 2024 – 2030, published by Grand View Research

Key Bipolar Disorder Company Insights

Some of the major companies in the global bipolar disorder market are AstraZeneca, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Pfizer, Inc. Companies are focusing on developing medicines and therapies in order to target various type of cancers. Companies are also focusing on reducing the side effects of medicines and treatments involved in treating bipolar disorders.

Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with health care providers, governments and local communities to support and expand access to health care around the world.

AstraZeneca plc is a pharmaceutical and biotechnology company, which offers products for various major diseases such as oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Key Bipolar Disorder Companies:

The following are the leading companies in the bipolar disorder market. These companies collectively hold the largest market share and dictate industry trends.

AstraZeneca
Eli Lilly and Company
GSK plc
Johnson & Johnson Services, Inc
Pfizer Inc.
AbbVie Inc.
Otsuka Holdings Co., Ltd.
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Sumitomo Pharma America, Inc.

Recent Developments

In December 2023, Bristol-Myers Squibb Company acquired Karuna Therapeutics, a biopharmaceutical company that develops medicines related to psychiatric and neurological conditions. This acquisition strengthened the neuroscience portfolio of Bristol-Myers Squibb Company.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com

Cardiac Rehabilitation Market Key Metrics: What Investors Should Know

The global cardiac rehabilitation market size is expected to reach USD 3.3 billion by 2030, at a CAGR of 6.0% according to a new report by Grand View Research, Inc. Rising incidence of lifestyle diseases such as cardiovascular conditions, obesity, and hyperlipidemia is one of the major factors responsible for growth. Technological innovations such as tele-cardiac rehabilitation, which means services provided from a distance using information technologies and telecommunications, are also another major driver of this market.

Furthermore, increase in number of health conscious people is boosting the cardiac rehabilitation market globally. The 2016 American College of Sports Medicine (ACSM) Worldwide Survey of Fitness Trends identified two new trends in the fitness industry, namely, flexibility & mobility rollers and smart phone exercise apps. This shows that people across the globe are becoming more health conscious and are using new products and techniques for better endurance.

Another factor propelling growth is supportive reimbursement pathways such as the Million Hearts initiative and the incentive payment model adopted by the Center for Medicare and Medicaid Services (CMS).

Access the Cardiac Rehabilitation Market Size, Share & Trends Analysis Report By Product (Treadmill, Elliptical Trainer, Stabilization Ball), By End-use (Rehabilitation Centers, Hospitals & Clinics), By Region, And Segment Forecasts, 2024 – 2030

Cardiac Rehabilitation Market Report Highlights

Treadmill dominated the market and accounted for a share of 24.1% in 2023. Regular exercise on treadmill reduces the risk of heart disease, enhances blood circulation and improves heart strength.

Blood pressure monitor is expected to witness the fastest CAGR of 6.8% during the forecast period, owing to rising prevalence of heart disease and CVDs.

The hospitals & clinics segment is projected to grow at the fastest CAGR of 8.5% over the forecast period

North America cardiac rehabilitation market held a dominant share in 2023. The U.S. cardiac rehabilitation dominated the North America market with a share of 88.4% in 2023.

Key Companies & Market Share Insights

Some of the key companies in the cardiac rehabilitation market include Omron Corporation; Ball Dynamics International, LLC; Core Health & Fitness, LLC; Koninklijke Philips N.V. (BioTelemetry Inc); GE Healthcare.

Omron is recognized for its medical devices like blood pressure monitors, digital thermometers, and nebulizers.

Order your free sample copy of “Cardiac Rehabilitation Market Report 2024 – 2030, published by Grand View Research

Key Cardiac Rehabilitation Companies:

The following are the leading companies in the cardiac rehabilitation market. These companies collectively hold the largest market share and dictate industry trends.

Ball Dynamics International, LLC
Core Health & Fitness, LLC
Honeywell International, Inc.
Omron Corporation
Koninklijke Philips N.V. (BioTelemetry Inc)
ICU Medical (Smiths Group)
Halma plc
GE Healthcare
Technogym
Johnson Health Tech

Recent Developments

In April 2024, The Virtual Cardiac Rehabilitation (VCR) Program was launched at Northern Health. The program is expected to help in patient recovery after heart condition, procedure or event.

In January 2024, North Suffolk Cardiology launched Pritikin Intensive Cardiac Rehabilitation Program (ICR). The program at every patient’s visit offers patients detailed lifestyle education and access to cardiac care team in the state of art location.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com